Severe Combined Immune Deficiency (SCID) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Severe Combined Immune Deficiency (SCID) – Drugs In Development, 2024 report and make more profitable business decisions.
Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections. The condition is fatal, usually within the first year or two of life, unless infants receive immune-restoring treatments such as transplants of blood-forming stem cells, gene therapy, or enzyme therapy.
The Severe Combined Immune Deficiency (SCID) drugs in development market research report provide comprehensive information on the therapeutics under development for Severe Combined Immune Deficiency (SCID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Combined Immune Deficiency (SCID) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Severe Combined Immune Deficiency (SCID) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Severe Combined Immune Deficiency (SCID) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Severe Combined Immune Deficiency (SCID) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Severe Combined Immune Deficiency (SCID) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Avixgen IncBoston Children's Hospital
Cellectis SA
Cellective BioTherapy Inc
Fred Hutchinson Cancer Research Center
Genethon SA
Jasper Therapeutics Inc
Mustang Bio Inc
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Smart Immune SAS
Taiga Biotechnologies Inc
The National Institute of Allergy and Infectious Diseases
University College London
University of California Los Angeles
University of California San Francisco
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Severe Combined Immune Deficiency (SCID) reports